Patents by Inventor Teresa Bennett
Teresa Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117030Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.Type: ApplicationFiled: February 28, 2023Publication date: April 11, 2024Inventors: Rita Diane AGOSTINELLI, James Reasoner APGAR, Eric Matthew BENNETT, Laird BLOOM, Ting CHEN, Aaron Michael D'ANTONA, Arnab DE, Fang JIN, Marion Teresa KASAIAN, Matthew Allister LAMBERT, Kimberly Ann MARQUETTE, Virginie MCMANUS, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Richard Thomas SHELDON, Lioudmila TCHISTIAKOVA, Alexander Michael Shuford BARRON, Richard Lee GIESECK, III, Xiaotian ZHONG
-
Patent number: 10507602Abstract: A modular accelerated cure system, for which the modules are of a size and weight to each be easily portable by one person, may be configured to fit a variety of parts, e.g., carbon fiber reinforced plastic (CFRP) components, such as found in the manufacture of composite aerospace structures. The system may be used to accelerate the cure of materials that allow elevated temperature cures, e.g., sealants, primers, coatings, paints, adhesives, and protective coatings, by increasing the ambient temperature surrounding a part, or a portion of the part, within each module in a controlled manner. The system is modular in that a number of modules may be fitted together to operate in unison and also may be adapted to fit parts of a variety of contours, shapes, and sizes. Temperature within each module may be controlled using a heat controller that receives a temperature indication from each module.Type: GrantFiled: August 17, 2016Date of Patent: December 17, 2019Assignee: THE BOEING COMPANYInventors: Joshua Paul Carlsen, Teresa Bennett, Timothy David Aquino, Eli Scott Fielden, Christopher Kovalenko, Ian Cox Matheson, Isabel Calderon Glasmann, Shane Rahrle, W. Taylor Peterson, Michael D. Ridges
-
Publication number: 20190212325Abstract: The invention presented here relates to a method for producing an artificial environment of primary cell populations, particularly an artificial tumor environment of primary tumor cell populations and its use in an ex vivo method to test the cellular responsiveness of primary tumor cell populations to a drug or drugs. The method of the invention comprises incubation of the primary tumor cells with the artificial tumor environment and the drug or drugs and analyze the response of the primary tumor cell populations. The incubation of the primary tumor cells with the artificial tumor environment, enhances the viability of said tumor cells and/or induces greater levels of tumor cell proliferation and, consequently, increases the sensitivity and accuracy of the test with regard to the drug/s assayed.Type: ApplicationFiled: November 4, 2016Publication date: July 11, 2019Inventors: Juan Antonio BALLESTEROS NOBELL, Teresa BENNETT, Daniel PRIMO RAMOS, Paolo PROSPERO GHIA, Ana Belén ESPINOSA OQUILLAS, Julián GORROCHATEGUI GUILLÉN, Alicia ROBLES MATEOS, Pilar HERNÁNDEZ CAMPO
-
Publication number: 20180050471Abstract: A modular accelerated cure system, for which the modules are of a size and weight to each be easily portable by one person, may be configured to fit a variety of parts, e.g., carbon fiber reinforced plastic (CFRP) components, such as found in the manufacture of composite aerospace structures. The system may be used to accelerate the cure of materials that allow elevated temperature cures, e.g., sealants, primers, coatings, paints, adhesives, and protective coatings, by increasing the ambient temperature surrounding a part, or a portion of the part, within each module in a controlled manner. The system is modular in that a number of modules may be fitted together to operate in unison and also may be adapted to fit parts of a variety of contours, shapes, and sizes. Temperature within each module may be controlled using a heat controller that receives a temperature indication from each module.Type: ApplicationFiled: August 17, 2016Publication date: February 22, 2018Inventors: Joshua Paul Carlsen, Teresa Bennett, Timothy David Aquino, Eli Scott Fielden, Christopher Kovalenko, Ian Cox Matheson, Isabel Calderon Glasmann, Shane Rahrle, W. Taylor Petersen, Michael D. Ridges
-
Publication number: 20170205395Abstract: Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs.Type: ApplicationFiled: March 16, 2017Publication date: July 20, 2017Inventors: Juan Ballesteros, Teresa Bennett, Daniel Primo, Alberto Orfao, Coyt Jackson, Santiago Lago, Maria Matoses, Lilia Suarez, Sandra Sapia, Andrew Bosanquet, Julian Corrochategui, Consuelo Tudela, Pilar Hernandez, Luis Ignacio Caveda
-
Publication number: 20110065172Abstract: A system and method of mixing and injecting discrete sample mixtures into a flow cytometer or other sample analysis apparatus may generally comprise a sample injection guide coupling a liquid handling apparatus with a sample analysis apparatus and facilitating injection of discrete sample mixtures into a fluidic system of the apparatus.Type: ApplicationFiled: November 18, 2010Publication date: March 17, 2011Applicant: Saryna Biotechnologies LLCInventors: Alex Okun, Teresa A. Bennett, Andrew Beemink, David J. Sieg, John T. Ransom
-
Patent number: 7858040Abstract: A system and method of mixing and injecting discrete sample mixtures into a flow cytometer or other sample analysis apparatus may generally comprise a sample injection guide coupling a liquid handling apparatus with a sample analysis apparatus and facilitating injection of discrete sample mixtures into a fluidic system of the apparatus.Type: GrantFiled: May 7, 2004Date of Patent: December 28, 2010Assignee: Saryna Biotechnologies LLCInventors: Alex Okun, Teresa A. Bennett, Andrew Beernink, David J. Sieg, John T. Ransom
-
Publication number: 20100298255Abstract: Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs.Type: ApplicationFiled: May 19, 2010Publication date: November 25, 2010Applicant: Vivia Biotech S.L.Inventors: Juan Ballesteros, Teresa Bennett, Daniel Primo, Alberto Orfao, Coyt Jackson, Santiago Lago, Maria Matoses, Lilia Suarez, Sandra Sapia, Andrew Bosanquet, Julian Gorrochategui, Consuelo Tudela, Pilar Hernandez, Luis Ignacio Caveda
-
Publication number: 20090264470Abstract: The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention.Type: ApplicationFiled: February 21, 2007Publication date: October 22, 2009Inventors: Teresa A. Bennett, James R. Hauske, Fu-Yue Zeng
-
Publication number: 20080027087Abstract: The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention.Type: ApplicationFiled: February 21, 2007Publication date: January 31, 2008Applicant: AMPLA Pharmaceuticals, Inc.Inventors: Teresa Bennett, James Hauske, Fu-Yue Zeng
-
Publication number: 20080027072Abstract: The present invention provides methods of treating obesity, eating disorders, and sexual dysfunction. The methods comprise administering to a mammalian host suffering from obesity, an eating disorder, or sexual dysfunction an effective dose of a compound of the invention. Also provided are methods of potentiating the effect of an MC4 receptor agonist in a mammalian host. In some cases the methods comprise administering to the host a compound that lowers the EC50 of the agonist. In other cases the methods comprise administering to the host a compound that increases the maximum effect of the agonist.Type: ApplicationFiled: April 19, 2007Publication date: January 31, 2008Applicant: AMPLA Pharmaceuticals, Inc.Inventors: Teresa Bennett, James Hauske, Fu-Yue Zeng
-
Publication number: 20050249635Abstract: A system and method of mixing and injecting discrete sample mixtures into a flow cytometer or other sample analysis apparatus may generally comprise a sample injection guide coupling a liquid handling apparatus with a sample analysis apparatus and facilitating injection of discrete sample mixtures into a fluidic system of the apparatus.Type: ApplicationFiled: May 7, 2004Publication date: November 10, 2005Applicant: Novasite Pharmaceuticals, Inc.Inventors: Alex Okun, Teresa Bennett, Andrew Beemink, David Sieg, John Ransom
-
Patent number: 6943268Abstract: The invention provides anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell, as well as inhibiting lymphocyte traffic through the lymph nodes. The invention further provides an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule. The invention additionally provides for suppression of inflammation and of lymph node entry by calmodulin antagonists that, like PDI inhibition, cause leukocyte L-selectin shedding.Type: GrantFiled: October 31, 2002Date of Patent: September 13, 2005Assignee: Science & Technology Corporation @ UNMInventors: Snezna Rogelj, Teresa A. Bennett, Larry A. Sklar
-
Publication number: 20050021241Abstract: The present disclosure provides compositions and methods for high throughput Gain of Function (GOF) sorting to discover and develop novel and highly selective candidate drug molecules. High throughput GOF sorting includes: mutating a single residue in a receptor and/or ligand; measuring the affinity and functional activity of the resulting ligand target-ligand interaction; and carrying out multiple rounds of mutation and measurement to determine which residues provide key interaction points underlying the functional activity of a ligand target-ligand interaction. Further, the present disclosure provides methods and compositions for high throughput and high precision GOF sorting, such that large numbers of mutations can be generated and screened rapidly, and GOF compounds can be identified and isolated.Type: ApplicationFiled: May 7, 2004Publication date: January 27, 2005Inventors: Juan Ballesteros, Teresa Bennett, Alex Okun, Andrew Beernink, John Ransom
-
Publication number: 20050009060Abstract: The present disclosure provides systems for multiplexed multitarget screening of cell populations having one or more wild type or mutated ligand targets and measuring cell responses to ligands using high throughput screening techniques, including flow cytometry (FCM). The method includes the steps of: 1) developing cell populations to be screened; 2) staining cell populations using one or more fluorochromes to yield a distinct excitation/emission signature for each cell population; 3) combining labelled cell populations into a single mixed suspension; 4) analyzing populations to resolve them on the basis of their unique signature; and 5) resolving individual populations and deconvoluting data to extract meaningful information about populations.Type: ApplicationFiled: May 7, 2004Publication date: January 13, 2005Inventors: Andrew Beernink, Teresa Bennett, Alex Okun, Juan Ballesteros, John Ransom
-
Publication number: 20030092763Abstract: The invention provides anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell, as well as inhibiting lymphocyte traffic through the lymph nodes. The invention further provides an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule. The invention additionally provides for suppression of inflammation and of lymph node entry by calmodulin antagonists that, like PDI inhibition, cause leukocyte L-selectin shedding.Type: ApplicationFiled: October 31, 2002Publication date: May 15, 2003Inventors: Snezna Rogelj, Teresa A. Bennett, Larry A. Sklar
-
Patent number: 6498189Abstract: The invention provides anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell, as well as inhibiting lymphocyte traffic through the lymph nodes. The invention further provides an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule. The invention additionally provides for suppression of inflammation and of lymph node entry by calmodulin antagonists that, like PDI inhibition, cause leukocyte L-selectin shedding.Type: GrantFiled: November 18, 1999Date of Patent: December 24, 2002Assignee: University of New MexicoInventors: Snezna Rogelj, Teresa A. Bennett, Larry A. Sklar